Neonatal Vitamin A supplementation and immune responses to oral polio vaccine in Zimbabwean infants

James A. Church, Sandra Rukobo, Margaret Govha, Marya P. Carmolli, Sean A. Diehl, Bernard Chasekwa, Robert Ntozini, Kuda Mutasa, Jean Hawes Humphrey, Beth D. Kirkpatrick, Andrew J. Prendergast

Research output: Contribution to journalArticle

Abstract

Background: Micronutrient deficiencies may contribute to reduced oral vaccine immunogenicity in developing countries. We hypothesised that neonatal vitamin A supplementation (NVAS) would improve oral vaccine responses. Methods: We performed a cross-sectional study of infants recruited at birth to the Zimbabwe Vitamin A for Mothers and Babies (ZVITAMBO) trial, a randomised controlled trial of single, high-dose NVAS vs placebo conducted in Zimbabwe between 1997-2001. We measured poliovirus-specific IgA to type 1-3 polio strains by semiquantitative capture ELISA in cryopreserved plasma samples collected at 6 months of age. Results: A total of 181 infants fulfilled inclusion criteria, of whom 80 were randomised to NVAS and 101 to placebo. There were no significant differences in baseline characteristics between groups. At 6 months of age, median (IQR) vaccine titres for infants randomised to NVAS vs placebo were 932 (421-3001) vs 1774 (711-5431) for Sabin-1 (p=0.04); 1361 (705-3402) vs 2309 (1081-4283) for Sabin-2 (p=0.15); and 1584 (796-4216) vs 2260 (996-5723) for Sabin-3 (p=0.14), respectively. After adjusting for breast feeding status, birth weight, season and infant sex in a linear regression model, there was only weak evidence of difference in log mean titres between vitamin A and placebo groups for Sabin-1 (p=0.08) and no evidence of difference in log mean titres for Sabin-2 and Sabin-3. Conclusions: NVAS did not augment oral polio vaccine responses in Zimbabwean infants. Further research is required to understand the impact of NVAS on responses to other oral vaccines.

Original languageEnglish (US)
Pages (from-to)110-115
Number of pages6
JournalTransactions of the Royal Society of Tropical Medicine and Hygiene
Volume113
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Poliomyelitis
Vitamin A
Vaccines
Placebos
Zimbabwe
Linear Models
Poliovirus
Micronutrients
Breast Feeding
Birth Weight
Immunoglobulin A
Developing Countries
Randomized Controlled Trials
Cross-Sectional Studies
Enzyme-Linked Immunosorbent Assay
Mothers
Parturition
Research

Keywords

  • Africa
  • Infants
  • OPV
  • Oral vaccine
  • Poliovirus
  • Vitamin A.

ASJC Scopus subject areas

  • Parasitology
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Church, J. A., Rukobo, S., Govha, M., Carmolli, M. P., Diehl, S. A., Chasekwa, B., ... Prendergast, A. J. (2019). Neonatal Vitamin A supplementation and immune responses to oral polio vaccine in Zimbabwean infants. Transactions of the Royal Society of Tropical Medicine and Hygiene, 113(3), 110-115. https://doi.org/10.1093/trstmh/try126

Neonatal Vitamin A supplementation and immune responses to oral polio vaccine in Zimbabwean infants. / Church, James A.; Rukobo, Sandra; Govha, Margaret; Carmolli, Marya P.; Diehl, Sean A.; Chasekwa, Bernard; Ntozini, Robert; Mutasa, Kuda; Humphrey, Jean Hawes; Kirkpatrick, Beth D.; Prendergast, Andrew J.

In: Transactions of the Royal Society of Tropical Medicine and Hygiene, Vol. 113, No. 3, 01.03.2019, p. 110-115.

Research output: Contribution to journalArticle

Church, JA, Rukobo, S, Govha, M, Carmolli, MP, Diehl, SA, Chasekwa, B, Ntozini, R, Mutasa, K, Humphrey, JH, Kirkpatrick, BD & Prendergast, AJ 2019, 'Neonatal Vitamin A supplementation and immune responses to oral polio vaccine in Zimbabwean infants', Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 113, no. 3, pp. 110-115. https://doi.org/10.1093/trstmh/try126
Church, James A. ; Rukobo, Sandra ; Govha, Margaret ; Carmolli, Marya P. ; Diehl, Sean A. ; Chasekwa, Bernard ; Ntozini, Robert ; Mutasa, Kuda ; Humphrey, Jean Hawes ; Kirkpatrick, Beth D. ; Prendergast, Andrew J. / Neonatal Vitamin A supplementation and immune responses to oral polio vaccine in Zimbabwean infants. In: Transactions of the Royal Society of Tropical Medicine and Hygiene. 2019 ; Vol. 113, No. 3. pp. 110-115.
@article{35ff517e5ad94d82881744a840414cdc,
title = "Neonatal Vitamin A supplementation and immune responses to oral polio vaccine in Zimbabwean infants",
abstract = "Background: Micronutrient deficiencies may contribute to reduced oral vaccine immunogenicity in developing countries. We hypothesised that neonatal vitamin A supplementation (NVAS) would improve oral vaccine responses. Methods: We performed a cross-sectional study of infants recruited at birth to the Zimbabwe Vitamin A for Mothers and Babies (ZVITAMBO) trial, a randomised controlled trial of single, high-dose NVAS vs placebo conducted in Zimbabwe between 1997-2001. We measured poliovirus-specific IgA to type 1-3 polio strains by semiquantitative capture ELISA in cryopreserved plasma samples collected at 6 months of age. Results: A total of 181 infants fulfilled inclusion criteria, of whom 80 were randomised to NVAS and 101 to placebo. There were no significant differences in baseline characteristics between groups. At 6 months of age, median (IQR) vaccine titres for infants randomised to NVAS vs placebo were 932 (421-3001) vs 1774 (711-5431) for Sabin-1 (p=0.04); 1361 (705-3402) vs 2309 (1081-4283) for Sabin-2 (p=0.15); and 1584 (796-4216) vs 2260 (996-5723) for Sabin-3 (p=0.14), respectively. After adjusting for breast feeding status, birth weight, season and infant sex in a linear regression model, there was only weak evidence of difference in log mean titres between vitamin A and placebo groups for Sabin-1 (p=0.08) and no evidence of difference in log mean titres for Sabin-2 and Sabin-3. Conclusions: NVAS did not augment oral polio vaccine responses in Zimbabwean infants. Further research is required to understand the impact of NVAS on responses to other oral vaccines.",
keywords = "Africa, Infants, OPV, Oral vaccine, Poliovirus, Vitamin A.",
author = "Church, {James A.} and Sandra Rukobo and Margaret Govha and Carmolli, {Marya P.} and Diehl, {Sean A.} and Bernard Chasekwa and Robert Ntozini and Kuda Mutasa and Humphrey, {Jean Hawes} and Kirkpatrick, {Beth D.} and Prendergast, {Andrew J.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1093/trstmh/try126",
language = "English (US)",
volume = "113",
pages = "110--115",
journal = "Transactions of the Royal Society of Tropical Medicine and Hygiene",
issn = "0035-9203",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Neonatal Vitamin A supplementation and immune responses to oral polio vaccine in Zimbabwean infants

AU - Church, James A.

AU - Rukobo, Sandra

AU - Govha, Margaret

AU - Carmolli, Marya P.

AU - Diehl, Sean A.

AU - Chasekwa, Bernard

AU - Ntozini, Robert

AU - Mutasa, Kuda

AU - Humphrey, Jean Hawes

AU - Kirkpatrick, Beth D.

AU - Prendergast, Andrew J.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: Micronutrient deficiencies may contribute to reduced oral vaccine immunogenicity in developing countries. We hypothesised that neonatal vitamin A supplementation (NVAS) would improve oral vaccine responses. Methods: We performed a cross-sectional study of infants recruited at birth to the Zimbabwe Vitamin A for Mothers and Babies (ZVITAMBO) trial, a randomised controlled trial of single, high-dose NVAS vs placebo conducted in Zimbabwe between 1997-2001. We measured poliovirus-specific IgA to type 1-3 polio strains by semiquantitative capture ELISA in cryopreserved plasma samples collected at 6 months of age. Results: A total of 181 infants fulfilled inclusion criteria, of whom 80 were randomised to NVAS and 101 to placebo. There were no significant differences in baseline characteristics between groups. At 6 months of age, median (IQR) vaccine titres for infants randomised to NVAS vs placebo were 932 (421-3001) vs 1774 (711-5431) for Sabin-1 (p=0.04); 1361 (705-3402) vs 2309 (1081-4283) for Sabin-2 (p=0.15); and 1584 (796-4216) vs 2260 (996-5723) for Sabin-3 (p=0.14), respectively. After adjusting for breast feeding status, birth weight, season and infant sex in a linear regression model, there was only weak evidence of difference in log mean titres between vitamin A and placebo groups for Sabin-1 (p=0.08) and no evidence of difference in log mean titres for Sabin-2 and Sabin-3. Conclusions: NVAS did not augment oral polio vaccine responses in Zimbabwean infants. Further research is required to understand the impact of NVAS on responses to other oral vaccines.

AB - Background: Micronutrient deficiencies may contribute to reduced oral vaccine immunogenicity in developing countries. We hypothesised that neonatal vitamin A supplementation (NVAS) would improve oral vaccine responses. Methods: We performed a cross-sectional study of infants recruited at birth to the Zimbabwe Vitamin A for Mothers and Babies (ZVITAMBO) trial, a randomised controlled trial of single, high-dose NVAS vs placebo conducted in Zimbabwe between 1997-2001. We measured poliovirus-specific IgA to type 1-3 polio strains by semiquantitative capture ELISA in cryopreserved plasma samples collected at 6 months of age. Results: A total of 181 infants fulfilled inclusion criteria, of whom 80 were randomised to NVAS and 101 to placebo. There were no significant differences in baseline characteristics between groups. At 6 months of age, median (IQR) vaccine titres for infants randomised to NVAS vs placebo were 932 (421-3001) vs 1774 (711-5431) for Sabin-1 (p=0.04); 1361 (705-3402) vs 2309 (1081-4283) for Sabin-2 (p=0.15); and 1584 (796-4216) vs 2260 (996-5723) for Sabin-3 (p=0.14), respectively. After adjusting for breast feeding status, birth weight, season and infant sex in a linear regression model, there was only weak evidence of difference in log mean titres between vitamin A and placebo groups for Sabin-1 (p=0.08) and no evidence of difference in log mean titres for Sabin-2 and Sabin-3. Conclusions: NVAS did not augment oral polio vaccine responses in Zimbabwean infants. Further research is required to understand the impact of NVAS on responses to other oral vaccines.

KW - Africa

KW - Infants

KW - OPV

KW - Oral vaccine

KW - Poliovirus

KW - Vitamin A.

UR - http://www.scopus.com/inward/record.url?scp=85062542499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062542499&partnerID=8YFLogxK

U2 - 10.1093/trstmh/try126

DO - 10.1093/trstmh/try126

M3 - Article

VL - 113

SP - 110

EP - 115

JO - Transactions of the Royal Society of Tropical Medicine and Hygiene

JF - Transactions of the Royal Society of Tropical Medicine and Hygiene

SN - 0035-9203

IS - 3

ER -